We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-1.7%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.94B
AUM Growth
-$132M
(-4.3%)
Cap. Flow
-$33.9M
Cap. Flow
% of AUM
-1.15%
Top 10 Holdings %
Top 10 Hldgs %
52.45%
Holding
59
New
22
Increased
10
Reduced
13
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$169M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$104M |
| 3 |
Zimmer Biomet
ZBH
|
+$95.7M |
| 4 |
Agilent Technologies
A
|
+$73.9M |
| 5 |
UnitedHealth
UNH
|
+$69.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$202M |
| 2 |
Medtronic
MDT
|
+$151M |
| 3 |
Incyte
INCY
|
+$110M |
| 4 |
CELG
Celgene Corp
CELG
|
+$100M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Zimmer Biomet
ZBH
$18.4B
| $254M | 8.62% |
2,394,750
+824,000
| +52% | +$95.7M |
|
|
2
Regeneron Pharmaceuticals
REGN
$76B
| $215M | 7.32% |
625,000
+300,000
| +92% | +$104M |
|
3
Merck
MRK
$321B
| $199M | 6.78% |
3,833,395
-253,805
| -6% | -$13.7M |
|
4
Labcorp
LH
$25.9B
| $170M | 5.78% |
1,222,200
-58,200
| -5% | -$8.55M |
|
|
5
Dentsply Sirona
XRAY
$2.75B
| $145M | 4.92% |
+2,875,000
| New | +$169M |
|
6
Baxter International
BAX
$13.8B
| $138M | 4.7% |
2,124,670
+399,670
| +23% | +$27M |
|
|
7
UnitedHealth
UNH
$383B
| $133M | 4.52% |
620,480
+305,480
| +97% | +$69.8M |
|
8
Intuitive Surgical
ISRG
$126B
| $117M | 3.97% |
847,260
+182,850
| +28% | +$25.5M |
|
9
LivaNova
LIVN
$4.45B
| $95.1M | 3.24% |
1,075,000
+452,003
| +73% | +$38.5M |
|
10
Pediatrix Medical
MD
$2.17B
| $76.9M | 2.62% |
1,383,200
+121,580
| +10% | +$6.66M |
|
11
Pacira BioSciences
PCRX
$1.06B
| $71.6M | 2.44% |
2,300,000
-500,000
| -18% | -$17.8M |
|
|
12
Agilent Technologies
A
$39.2B
| $70.5M | 2.4% |
+1,054,000
| New | +$73.9M |
|
|
RDUS
13
DELISTED
Radius Health, Inc.
RDUS
| $68.3M | 2.32% |
+1,900,000
| New | +$68.6M |
|
|
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
| $65.1M | 2.21% |
+1,200,000
| New | +$67.1M |
|
15
Qiagen
QGEN
$8.55B
| $64.8M | 2.21% |
+1,892,562
| New | +$66.5M |
|
|
CELG
16
DELISTED
Celgene Corp
CELG
| $60.8M | 2.07% |
681,030
-1,043,970
| -61% | -$100M |
|
17
Elevance Health
ELV
$81.6B
| $59M | 2.01% |
268,770
-47,410
| -15% | -$11.1M |
|
18
Neurocrine Biosciences
NBIX
$18.7B
| $57.4M | 1.95% |
691,595
-833,405
| -55% | -$70.4M |
|
19
Danaher
DHR
$138B
| $55.6M | 1.89% |
640,659
+500,043
| +356% | +$43.7M |
|
20
AbbVie
ABBV
$455B
| $54.3M | 1.85% |
574,070
-175,340
| -23% | -$19.3M |
|
21
IQVIA
IQV
$39.1B
| $54.1M | 1.84% |
550,930
-232,450
| -30% | -$23.5M |
|
|
MASI
22
DELISTED
Masimo
MASI
| $50.6M | 1.72% |
+575,000
| New | +$50.1M |
|
|
23
CALL
Incyte
INCY
$24.9B
| $50M | 1.7% |
+600,000
| New | +$54.1M |
|
24
Gilead Sciences
GILD
$163B
| $49.5M | 1.68% |
+656,690
| New | +$52.2M |
|
|
AGN
25
DELISTED
Allergan plc
AGN
| $49.1M | 1.67% |
291,520
-533,480
| -65% | -$89.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2018 Portfolio in Review
As of Q1 2018, HealthCor Management held 59 positions worth $2.94B, down 4.3% from $3.07B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
HealthCor Management's Q1 2018 filing shows 22 new, 10 increased, 13 reduced and 13 closed positions. Its largest new stake was Dentsply Sirona: 2,875,000 shares worth $145M. The largest sale was Bioverativ Inc. Common Stock, an estimated $202M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 100% a quarter earlier.
- HealthCor Management's largest Q1 2018 buy was Dentsply Sirona: 2,875,000 shares worth $145M.
- HealthCor Management added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $104M increase.
- HealthCor Management's biggest Q1 2018 reduction was Medtronic, cutting an estimated $151M.
- HealthCor Management fully exited Bioverativ Inc. Common Stock in Q1 2018, selling an estimated $202M.
- HealthCor Management's ten largest holdings make up 52% of its $2.94B portfolio in Q1 2018.
- HealthCor Management opened 22 new positions and closed 13 in Q1 2018.
- HealthCor Management's portfolio value fell 4.3% quarter-over-quarter to $2.94B.
Based on HealthCor Management's 13F filing for Q1 2018, filed 15 May 2018.